Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Balanced Outlook Amidst Strategic Shifts: Pfizer's Hold Rating Explained
Pfizer's Acoramidis Shows Promising Survival Trends: A Buy Rating Endorsement
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Wells Fargo Remains a Hold on Pfizer (PFE)
DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating
Big Bank Ratings | Damo: Raising Pfizer's target price to $29 and is cautiously optimistic about this year's outlook
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
Pfizer Analyst Ratings
Major Bank Ratings | J.P. Morgan Chase: Pfizer's sales of core products in the first quarter met expectations and maintained a “neutral” rating
Pfizer Exceeds Q1 Expectations With Strong Earnings and Raises 2024 Guidance: A Buy Rating by Evan Seigerman
Leerink Adjusts Price Target on Pfizer to $29 From $27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Alkermes (ALKS)